Get the app
US › Healthcare

Fulgent Genetics Inc (FLGT)

US · Healthcare · Diagnostics & Research

$19.81-7.17%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$85.4M
Revenue YoY
+4.4%
Net profit
$-29.5M
EPS
$-0.88
EPS estimate
$-0.79
Net margin
-34.6%

EPS came in at -0.88 against a street estimate of -0.79 — a miss of 11.4%.

Key statistics

Market cap
$579.5M
Forward P/E
7.7
P/B
0.58
Book value
$36.40
EPS (TTM)
$-2.82
52-week high
$31.04
52-week low
$13.46
50-day MA
$20.33
200-day MA
$19.79
Beta
0.93

Analyst view

Analysts rate Fulgent Genetics Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $19.00.

Shareholding

Insiders
37.75%
Institutions
58.31%

Largest institutional holders

FundStake
BlackRock Inc8.31%
Acadian Asset Management LLC3.70%
Vanguard Capital Management, LLC2.87%
Jacobs Levy Equity Management, Inc.2.84%
JPMorgan Chase & Co2.75%
Diametric Capital, LP2.54%
Ameriprise Financial Inc2.44%
Dimensional Fund Advisors, Inc.2.27%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fulgent Genetics Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.